Psivida Ltd. (PSDV)
()
 
 

Overview

pSivida is a global drug delivery company committed to the biomedical sector. Retisert® is FDA approved for the treatment of uveitis. Vitrasert® is FDA approved for the treatment of AIDS-related CMV Retinitis. Bausch & Lomb own the trademarks Vitrasert® and Retisert®. pSivida has licensed the technologies underlying both of these products to Bausch & Lomb. The technology underlying Medidur(TM) for diabetic macular edema is licensed to Alimera Sciences and is in Phase III clinical trials. pSivida has a worldwide collaborative research and license agreement with Pfizer Inc. for other ophthalmic applications of the Durasert(TM) technology which underpins the Medidur product.


Contact Information

Level 12 BGC Centre
28 The Esplanade
Perth, WA6000

tel: 61 8 9226 5099
fax: 61 8 9226 5499
http://www.psivida.com.au

,  



Investor Relations



tel:
fax:




Stock

Exchange: NASDAQ
Industry: Scientific & Technical Instruments
Market Cap: $86.9M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.